Corthésy Blaise
R & D Laboratory of the Division of Immunology and Allergy, State University Hospital (CHUV) HO 05-1542, Avenue Pierre Decker, CH-1005 Lausanne, Switzerland.
Trends Biotechnol. 2002 Feb;20(2):65-71. doi: 10.1016/s0167-7799(01)01874-1.
The use of monoclonal antibodies has become routine in research and diagnostic laboratories but the potential level of antibodies in use in public health and medical applications is still far from its maximum. From a clinical perspective, topical immunotherapy of mucosal surfaces with monoclonal antibodies can block entry and transmission of bacteria, viruses, fungi and parasites that infect humans, and defeat some key strategies, evolved by many pathogens, to evade the host immune system. The chief antibody at mucosal surfaces is secretory immunoglobulin A (SIgA), a multi-polypeptide complex originating from two cell types. The recent design of heterologous expression systems, coupled with modern biotechnology processes, should form a sound basis for studying the functional properties of SIgAs and evaluate their value as biotherapeutics. Here, we discuss the principles underlying mucosal immunity and review the application of recombinant SIgA to the dissection of mechanisms in passive and active protection at mucosal surfaces.
单克隆抗体的使用在研究和诊断实验室已成为常规操作,但在公共卫生和医学应用中所使用抗体的潜在水平仍远未达到最大值。从临床角度来看,用单克隆抗体对黏膜表面进行局部免疫疗法可以阻断感染人类的细菌、病毒、真菌和寄生虫的侵入与传播,并挫败许多病原体为逃避宿主免疫系统而演化出的一些关键策略。黏膜表面的主要抗体是分泌型免疫球蛋白A(SIgA),它是一种源自两种细胞类型的多聚体复合物。最近设计的异源表达系统,再结合现代生物技术工艺,应为研究SIgA的功能特性并评估其作为生物治疗剂的价值奠定坚实基础。在此,我们讨论黏膜免疫的基本原理,并综述重组SIgA在剖析黏膜表面被动和主动保护机制方面的应用。